MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$2,972,403
Free Cash flow
-$12,052,953
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Proceeds from issuance of common...
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Net loss
Accounts payable and accrued exp...
Accounts receivable
Others
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Cash Flow
2026-06-30
2025-06-30
Net loss
-12,468,672
-10,604,886
Depreciation and amortization
1,163,847
-
Impairment of long-lived assets
298,555
220,062
Provision for credit losses
9,974
546
Amortization of right-of-use assets
-
243,632
Inventory write-downs
62,044
0
Depreciation and amortization
-
970,117
Stock-based compensation
195,208
238,045
Non-cash adjustment on r&d expenditure claims
-124,924
137,696
Non-cash other operating activities
87,933
-113,645
Accounts receivable
253,850
164,910
Non-cash loss on foreign currency translation, net
-
0
Inventories
-216,638
-142,322
Research and development tax incentive receivable
72,543
209,076
Other current assets
203,956
329,404
Accounts payable and accrued expenses
-684,743
2,577,151
Grant receivable / deferred grant income
-
2,486,668
Long-term employee benefit liabilities
-34,990
21,306
Fair value gain on revaluation of holdback series c preferred stock
-
0
Operating lease liabilities
-191,725
-271,499
Net cash used in operating activities
-11,927,222
-9,677,313
Proceeds from sale of assets held for sale
40,158
-
Purchase of property and equipment
125,731
231,838
Net cash used in investing activities
-85,573
-231,838
Proceeds from exercise of warrants, net of issuance costs
-
7,939
Proceeds from private placement, net of issuance costs
-
0
Proceeds from issuance of common stock, net of issuance costs
10,699,794
4,589,866
Proceeds from issuance of common stock for warrants exercised, net of issuance costs
4,283,912
-
Net cash provided by financing activities
14,983,706
4,597,805
Effect of foreign exchange rates on cash and cash equivalents
1,492
27,157
Net increase (decrease) in cash and cash equivalents
2,972,403
-5,284,189
Cash and cash equivalents, beginning of period
1,019,909
-
Cash and cash equivalents, end of the period
3,992,312
-
Page 1
Unit: Dollar.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock, net of...
$10,699,794
(133.12%↑ Y/Y)
Proceeds from issuance of
common stock for...
$4,283,912
Net cash provided by
financing activities
$14,983,706
(225.89%↑ Y/Y)
Effect of foreign
exchange rates on cash and...
$1,492
(-94.51%↓ Y/Y)
Net increase
(decrease) in cash and cash...
$2,972,403
(156.25%↑ Y/Y)
Canceled cashflow
$12,012,795
Depreciation and
amortization
$1,163,847
(19.97%↑ Y/Y)
Impairment of long-lived
assets
$298,555
(35.67%↑ Y/Y)
Inventories
-$216,638
(-52.22%↓ Y/Y)
Stock-based compensation
$195,208
(-18.00%↓ Y/Y)
Non-cash adjustment on
r&d expenditure...
-$124,924
(-190.72%↓ Y/Y)
Inventory write-downs
$62,044
Provision for credit
losses
$9,974
(1726.74%↑ Y/Y)
Proceeds from sale of
assets held for sale
$40,158
Net cash used in
operating activities
-$11,927,222
(-23.25%↓ Y/Y)
Net cash used in
investing activities
-$85,573
(63.09%↑ Y/Y)
Canceled cashflow
$2,071,190
Canceled cashflow
$40,158
Net loss
-$12,468,672
(-17.57%↓ Y/Y)
Purchase of property and
equipment
$125,731
(-45.77%↓ Y/Y)
Accounts payable and
accrued expenses
-$684,743
(-126.57%↓ Y/Y)
Accounts receivable
$253,850
(53.93%↑ Y/Y)
Other current assets
$203,956
(-38.08%↓ Y/Y)
Operating lease
liabilities
-$191,725
(29.38%↑ Y/Y)
Non-cash other operating
activities
$87,933
(177.38%↑ Y/Y)
Research and development
tax incentive...
$72,543
(-65.30%↓ Y/Y)
Long-term employee
benefit liabilities
-$34,990
(-264.23%↓ Y/Y)
Buy us a coffee
INTELLIGENT BIO SOLUTIONS INC. (INBS)
INTELLIGENT BIO SOLUTIONS INC. (INBS)